Zaknoen Sara 4

What Happened Sara Zaknoen, a director of aTYR PHARMA, was granted a derivative award of 50,000 shares on May 11, 2026. The transaction is reported as an award/grant (code A) at $0.00 per share (total reported value $0). The filing’s footnote identifies the award as an option granted under the company’s non-employee director compensation policy.

Key Details

• Transaction date: May 11, 2026; Filing date: May 13, 2026 (filed two days later — appears timely).
• Instrument/price: Derivative award (option per footnote), 50,000 shares, reported price $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting: The option vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer’s 2027 Annual Meeting of Stockholders, subject to continued board service (footnote).
• No sale or exercise occurred — this is an award grant, not a cash exercise or open‑market trade.

Context Grants to non-employee directors are a common form of compensation and do not by themselves indicate buying or selling sentiment in the market. As a derivative award (an option) it will only convert into actual shares if/when vested and exercised according to the plan terms.